Company intelligence / Profile preview

BTB Purchaser

Wilmington, Delaware, United States

Ownership: Private
Development stage: Other

Overview

BTB Purchaser, LLC is a special purpose acquisition vehicle and a subsidiary of AbbVie, specifically formed to facilitate the acquisition of ImmunoGen. In late 2023, AbbVie utilized this entity to initiate a tender offer for all outstanding shares of ImmunoGen for approximately $10.1 billion. The transaction was designed to integrate ImmunoGen's flagship antibody-drug conjugate, Elahere, into AbbVie's oncology portfolio. Following the successful completion of the merger in February 2024, the entity served its primary purpose in the corporate restructuring process.

Industry: Investors

Beyond the preview

Go deeper on BTB Purchaser.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BTB Purchaser.

Explore the full profile